VC
KTTA icon

Vivo Capital’s Pasithea Therapeutics KTTA Stock Holding History

Vivo Capital’s Portfolio KTTA Stock Details KTTA Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$1.56M Hold
2,100,000
– – 0.13% 43
2025
Q4 		$2.71M Buy
+2,100,000
New +$1.85M 0.18% 43

Other funds holding KTTA

Janus Henderson Group
Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return
Adage Capital Partners
Adage Capital Partners Boston, Massachusetts $64.8B AUM 42.7% 1-Year Est. Return
SCM
Squadron Capital Management Westmont, Illinois $273M AUM
Ameriprise
Ameriprise Minneapolis, Minnesota $432B AUM 30.22% 1-Year Est. Return
CCC
Cable Car Capital San Francisco, California $289M AUM 26.33% 1-Year Est. Return
SCM
Stonepine Capital Management Bend, Oregon $250M AUM 77.6% 1-Year Est. Return
AI
AdvisorShares Investments Bethesda, Maryland $549M AUM 32.58% 1-Year Est. Return
PAP
Persistent Asset Partners Hong Kong $268M AUM 158.98% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return

Vivo Capital's KTTA Position: Q1 2026 in Review

Vivo Capital held its Pasithea Therapeutics (KTTA) position steady in Q1 2026 at 2,100,000 shares worth $1.56M. The position accounts for 0.13% of the portfolio, ranked #43.

Vivo Capital first reported a position in KTTA in Q4 2025 and has held it in 2 quarters since. The position peaked at $2.71M in Q4 2025. 21 funds tracked by Wall St. Rank hold KTTA as of Q1 2026.

  • Vivo Capital held 2,100,000 shares of Pasithea Therapeutics worth $1.56M as of Q1 2026.
  • Vivo Capital left its Pasithea Therapeutics share count unchanged in Q1 2026.
  • Pasithea Therapeutics made up 0.13% of Vivo Capital's portfolio in Q1 2026, its #43 holding.
  • Vivo Capital first reported a position in Pasithea Therapeutics in Q4 2025 and has held it in 2 quarters since.
  • Vivo Capital's Pasithea Therapeutics position peaked at $2.71M in Q4 2025.
  • 21 funds tracked by Wall St. Rank held Pasithea Therapeutics as of Q1 2026.

Based on Vivo Capital's 13F filing for Q1 2026, filed 15 May 2026.